The iCHOR iDVT venous reperfusion system has demonstrated consistent safety, efficacy, and procedural performance across a diverse spectrum of clinical presentations in limited market release evaluation accessing patients in both Hospital and Ambulatory settings.
Clinical Evidence at a Glance
In 77 documented procedures performed by 20 physicians, the iDVT platform achieved:
- 95% technical success rate and 93.5% procedural success rate
- Mean treatment zone of 231 mm across varying clot morphologies and vessel anatomies
- Average vessel diameter of 13.2 mm, demonstrating versatility across venous territories
- Minimal blood loss (<5 mL) across all procedures, supporting favorable safety and efficacy endpoints
- No observed vessel integrity procedural issues or post thrombotic issues at 30 days
- Mean treatment time of 29.4 minutes, reflecting efficient procedural workflow including multiple sweeps to clear the path (reperfusion), treat the underlying lesion, and access sheath removal.
Physician Adoption and Satisfaction
The emergence of repeat utilization underscores growing physician confidence: 88.3% of all procedures were performed by physicians who progressed beyond initial evaluation. Device performance ratings consistently exceeded 4.5/5.0 across packaging, catheter tracking, and ease of delivery with 100% of respondents indicating intent to continue use.
A Platform Designed for Real-World Integration
The iDVT system requires no aspiration pumps, no thrombolytic infusion, no surgery, no capital equipment enabling seamless integration into hospital, office-based laboratory (OBL), and ambulatory surgery center (ASC) environments.
Read the full iDVT 14F Clinical Data Summary here.
